Doxorubicin for Breast Cancer: 106 Real Stories

106 stories match breast cancer and doxorubicin. 100 of them mention surgery.

Kattysmith, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Kattysmith's Patient Story

Patient Info: Kattysmith, Female, 60s | Stage IV

Metastatic Site: lymphatic system; skin/soft-tissue nodules; possible…

After AC chemotherapy, the metastatic nodules shrank markedly. Kattysmith was stable on palbociclib and letrozole with declining tumor markers, while clearly stating that she was not NED.

breastcancer.org
OutcomeResponding Well
Stephanie, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II BRCA1 Invasive Ductal Carcinoma: Stephanie's Patient Story

Patient Info: Stephanie Hargis, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

Stephanie had Stage II triple-negative breast cancer with BRCA1 mutation, then a local recurrence in April 2023 without distant spread; after surgery, chemotherapy, Keytruda, radiation, and Lynparza, she remained in ongoing post-recurrence treatment.

BreastCancer.org (ES)
OutcomeCare Ongoing
Cher, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Cher's Survivor Story

Patient Info: Cher, Female | Stage III

Biomarkers: Hormone-positive; HER2-negative; Oncotype DX score 0

No evidence of disease after treatment for Stage IIIB breast cancer, with ongoing adjuvant Verzenio, long-term hormone blockers, and planned preventive mastectomy/DIEP flap reconstruction.

breastcancer.org
OutcomeCancer-Free / NED
Nicole, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Nicole's Survivor Story

Patient Info: Nicole Grogan, Female, 40s | Stage II

Nicole completed surgery, chemotherapy, radiation and the exercise trial, and had no evidence of disease at her July 2019 appointment.

Memorial Sloan Kettering
OutcomeCancer-Free / NED
Michelle, who was diagnosed with Stage I Breast CancerBreast Cancer

Stage I Breast Cancer: Michelle's Survivor Story

Patient Info: Michelle Kang, Female, Under 40 | Stage I

Biomarkers: Hormone-positive breast cancer; no suspicious inherited genetic mutation reported

Michelle was 6 years cancer-free after Stage 1B hormone-positive breast cancer while continuing hormone therapy, Zometa, Signatera blood testing, reconstruction follow-up, and survivorship monitoring.

City of Hope
OutcomeCancer-Free / NED
Naomi, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Naomi's Patient Story

Patient Info: Naomi Arbel-Brodd, Female | Stage II

Twenty years after her 2006 diagnosis, she had returned to UT MD Anderson as a weekly volunteer supporting other women receiving breast cancer care.

MD Anderson
OutcomeNot reported
Alison, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient Story
OutcomeLiving With Cancer / Remission
Melissa, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Triple-Negative Breast Cancer: Melissa's Survivor Story

Patient Info: Melissa, Female | Stage II

Biomarkers: Triple-negative breast cancer; BRCA testing negative; NBN gene mutation identified on later testing

Melissa completed pregnancy-adapted cancer treatment, later underwent risk-reducing surgery and reconstruction, and was raising both daughters.

The Patient Story
OutcomeTreatment Completed / Survivorship
Bethany, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage II

Biomarkers: ER-positive; hormone-positive

As of June 2026, Bethany described care for late Stage II/early Stage III ER-positive breast cancer, beginning with AC chemotherapy and Taxol after scans showed no distant spread, with surgery, radiation, and hormone therapy planned as next phases.

The Patient Story
OutcomeCare Ongoing
Callie, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Callie's Survivor Story

Patient Info: Callie, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of June 2026, Callie described survivorship after mastectomy, ACT chemotherapy, reconstruction, and hysterectomy for Stage IIB ER-positive IDC, with all cancer-directed treatment completed by the end of 2019.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Tina, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Tina's Patient Story

Patient Info: Tina, Female, Under 40 | Stage III

Biomarkers: ER-positive

As of June 2026, Tina was in survivorship after double mastectomy, AC-T chemotherapy, radiation, and ongoing hormone therapy with daily tamoxifen and Zoladex every 3 months.

The Patient Story
OutcomeCare Ongoing
Janice, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Triple-Negative Breast Cancer: Janice's Patient Story

Patient Info: Janice, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: Other sites not specified

Living with incurable Stage IV triple-negative breast cancer while advocating for dose adjustments, symptom management, and balancing quality of life with survival.

The Patient Story
OutcomeLiving With Cancer
Erin, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Triple-Negative Breast Cancer: Erin's Patient Story

Patient Info: Erin, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; later tumor responded to androgen signaling

Metastatic Site: Lung; brain

As of June 2026, Erin was living with metastatic triple-negative breast cancer involving lung and brain, with tumors shrinking on ongoing Gemzar plus carboplatin chemotherapy every 2 weeks.

The Patient Story
OutcomeResponding Well
Monica, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II Invasive Ductal Carcinoma: Monica's Survivor Story

Patient Info: Monica, Female, Under 40 | Stage II

As of June 2026, Monica described survivorship after treatment for Stage IIB breast cancer and a separate undifferentiated pleomorphic sarcoma, with lasting neuropathy, bone pain, reconstruction complications, and grief around fertility.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Renee, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV HER2-Positive Invasive Ductal Carcinoma: Renee's Patient Story

Patient Info: Renee N., Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain

As of June 2026, Renee’s public story described living with metastatic HER2-positive breast cancer as a chronic illness, after brain radiation and while on Kadcyla every 3 weeks with stable scans reported in December 2019 and early March 2020.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Breast CancerBreast Cancer

Triple-negative breast cancer diagnosed during pregnancy: remission

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

The patient remains in remission 30 months after surgery. Immune-related brachial plexopathy after treatment improved after steroids, IVIG, and plasmapheresis, with electrophysiologic resolution and near-complete strength and sensory recovery.

PubMed Central
OutcomeCancer-Free / NED
Caroline, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III HER2-Positive Breast Cancer: Caroline's Patient Story

Patient Info: Caroline McNally, Female, Under 40 | Stage III

Biomarkers: Hormone-positive component reported; exact ER/PR/HER2 panel not stated

As of February 2026, Caroline was in active treatment for Stage III hormone-positive breast cancer, receiving Taxol after dose-dense AC and preparing for double mastectomy, likely radiation, and hormone therapy.

Susan G. Komen
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 breast cancer: 4 years and counting

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor: hormone receptor-positive; HER2 1+. Metastatic recurrence: triple-negative breast cancer.

Metastatic Site: liver, bone, lung, supraclavicular lymph nodes,…

After response of choroidal metastases to eye radiation plus sacituzumab govitecan, disease progressed in February 2023 with cerebellar and pituitary brain lesions; she developed obstructive hydrocephalus, entered hospice in May 2023, and died in June 2023.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage III Breast Cancer Treatment Complicated by Coronary Thrombosis

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 25–30%

She achieved complete remission about 12 months after the myocardial infarction and remained in complete oncologic remission at 44 months.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast CancerBreast Cancer

Hormone receptor-positive breast cancer treated with pembrolizumab trial complicated by acquired lipodystrophy

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-negative breast cancer. Metabolic changes occurred during/after pembrolizumab.

As of December 2025, breast cancer treatment had included neoadjuvant chemotherapy/pembrolizumab, surgery, adjuvant pembrolizumab, and endocrine therapy; CT did not show recurrence during weight-loss evaluation, but she required ongoing metabolic care for pembrolizumab-associated acquired generalized lipodystrophy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed Central
OutcomeCancer-Free / NED